Literature DB >> 23021261

Performance of commercially available serological diagnostic tests to detect Leishmania infantum infection on experimentally infected dogs.

Alhelí Rodríguez-Cortés1, Ana Ojeda, Felicitat Todolí, Jordi Alberola.   

Abstract

Leishmania infantum (syn. Leishmania chagasi) is the etiological agent of a widespread serious zoonotic disease that affects both humans and dogs. Prevalence and incidence of the canine infection are important parameters to determine the risk and the ways to control this reemergent zoonosis. Unfortunately, there is not a gold standard test for Leishmania infection. Our aim was to assess the operative validity of commercial tests used to detect antibodies to Leishmania in serum samples from experimental infections. Three ELISA tests (LEISCAN(®) Leishmania ELISA Test, INGEZIM(®) LEISHMANIA, and INGEZIM(®) LEISHMANIA VET), three immunochromatographic tests (INGEZIM(®) LEISHMACROM, SNAP(®) Leishmania, and WITNESS(®) Leishmania), and one IFAT were evaluated. LEISCAN(®) Leishmania ELISA test achieved the highest sensitivity and accuracy (both 0.98). Specificity was 1 for all tests except for IFAT. All tests but IFAT obtained a positive predictive value of 1, while the maximum negative predictive value was achieved by LEISCAN(®) Leishmania ELISA Test (0.93). The best positive likelihood ratio was obtained by INGEZIM(®) LEISHMANIA VET (30.26), while the best negative likelihood ratio was obtained by LEISCAN(®) Leishmania ELISA Test (0.02). The highest diagnostic odds ratio was achieved by LEISCAN(®) Leishmania ELISA Test (729.00). The largest area under the ROC curve was obtained by LEISCAN(®) Leishmania ELISA Test (0.981). Quantitative ELISA based tests performmed better than qualitative tests ("Rapid Tests"), and the test best suited to detect Leishmania in infected dogs and to provide clinically useful information was LEISCAN(®) Leishmania ELISA Test. This and other results point also to the need of revising the status of IFAT as a gold standard for the diagnosis of leishmaniasis.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23021261     DOI: 10.1016/j.vetpar.2012.09.009

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  16 in total

1.  Semi-quantitative measurement of asymptomatic L. infantum infection and symptomatic visceral leishmaniasis in dogs using Dual-Path Platform® CVL.

Authors:  Mandy Larson; Angela Toepp; Benjamin Scott; Melissa Kurtz; Hailie Fowler; Javan Esfandiari; Randall F Howard; Aarthy C Vallur; Malcolm S Duthie; Christine Petersen
Journal:  Appl Microbiol Biotechnol       Date:  2016-10-31       Impact factor: 4.813

Review 2.  A new Leishmania-specific hypothetical protein and its non-described specific B cell conformational epitope applied in the serodiagnosis of canine visceral leishmaniasis.

Authors:  Daniela P Lage; Vívian T Martins; Mariana C Duarte; Lourena E Costa; Esther Garde; Laura M Dimer; Amanda C S Kursancew; Miguel A Chávez-Fumagalli; Danielle F de Magalhães-Soares; Daniel Menezes-Souza; Bruno M Roatt; Ricardo A Machado-de-Ávila; Manuel Soto; Carlos A P Tavares; Eduardo A F Coelho
Journal:  Parasitol Res       Date:  2016-01-19       Impact factor: 2.289

3.  Subtractive phage display selection from canine visceral leishmaniasis identifies novel epitopes that mimic Leishmania infantum antigens with potential serodiagnosis applications.

Authors:  Lourena E Costa; Mayara I S Lima; Miguel A Chávez-Fumagalli; Daniel Menezes-Souza; Vivian T Martins; Mariana C Duarte; Paula S Lage; Eliane G P Lopes; Daniela P Lage; Tatiana G Ribeiro; Pedro H R Andrade; Danielle F de Magalhães-Soares; Manuel Soto; Carlos A P Tavares; Luiz R Goulart; Eduardo A F Coelho
Journal:  Clin Vaccine Immunol       Date:  2013-11-20

4.  Serological diagnosis of canine leishmaniosis: comparison of three commercially available tests.

Authors:  Denis Wolf; Klaus Failing; Anja Taubert; Nikola Pantchev
Journal:  Parasitol Res       Date:  2014-04-10       Impact factor: 2.289

5.  Modelling canine leishmaniasis spread to non-endemic areas of Europe.

Authors:  L A Espejo; S Costard; F J Zagmutt
Journal:  Epidemiol Infect       Date:  2014-10-27       Impact factor: 4.434

6.  Estimation of canine Leishmania infection prevalence in six cities of the Algerian littoral zone using a Bayesian approach.

Authors:  Amel Adel; Emmanuel Abatih; Niko Speybroeck; Abdelkrim Soukehal; Rachid Bouguedour; Karim Boughalem; Abdelmalek Bouhbal; Mouloud Djerbal; Claude Saegerman; Dirk Berkvens
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

7.  Serological diagnosis of canine leishmaniosis: comparison of three commercial ELISA tests (Leiscan, ID Screen and Leishmania 96), a rapid test (Speed Leish K) and an in-house IFAT.

Authors:  Laia Solano-Gallego; Sergio Villanueva-Saz; Marta Carbonell; Michele Trotta; Tommaso Furlanello; Alda Natale
Journal:  Parasit Vectors       Date:  2014-03-24       Impact factor: 3.876

Review 8.  Evaluation of Immunofluorescence Antibody Test Used for the Diagnosis of Canine Leishmaniasis in the Mediterranean Basin: A Systematic Review and Meta-Analysis.

Authors:  Amel Adel; Dirk Berkvens; Emmanuel Abatih; Abdelkrim Soukehal; Juana Bianchini; Claude Saegerman
Journal:  PLoS One       Date:  2016-08-18       Impact factor: 3.240

9.  Performance of Leishmania PFR1 recombinant antigen in serological diagnosis of asymptomatic canine leishmaniosis by ELISA.

Authors:  Darién Ledesma; Eduardo Berriatua; M Carmen Thomas; Luis Jesús Bernal; María Ortuño; Celia Benitez; Adriana Egui; Kostas Papasouliotis; Bryn Tennant; Julia Chambers; Juan José Infante; Manuel Carlos López
Journal:  BMC Vet Res       Date:  2017-10-23       Impact factor: 2.741

10.  Factors associated with the seroprevalence of leishmaniasis in dogs living around Atlantic Forest fragments.

Authors:  Nelson Henrique de Almeida Curi; Ana Maria de Oliveira Paschoal; Rodrigo Lima Massara; Andreza Pain Marcelino; Adriana Aparecida Ribeiro; Marcelo Passamani; Guilherme Ramos Demétrio; Adriano Garcia Chiarello
Journal:  PLoS One       Date:  2014-08-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.